We recently compiled a list of the 10 Best FTSE Dividend Stocks To Buy Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other FTSE dividend stocks.
The first half of 2024 has been notable for the UK equity market, as the FTSE 100, the benchmark index for UK company shares, hit a record high. However, stocks tumbled in the first week of June as financial shares mirrored broader losses in European markets. That was mainly due to the political uncertainty that unsettled investors and a slump in industrial mining stocks further dragged down the market. That said, with some time remaining in the general elections, there is still some potential for additional developments and surprises within the UK market. The index is up by nearly 6% this year so far, compared with a 14.3% return of the broader US market
The Bank of England (BoE) was one of the first central banks to begin increasing interest rates after the peak of the COVID pandemic. From December 2021 to August 2023, it raised the bank rate by 515 basis points to a 16-year high of 5.25% in order to address rising inflationary pressures in the economy. According to a Reuters poll of economists, the BoE is expected to begin cutting interest rates in August. Most economists also anticipate at least one more rate reduction this year, despite ongoing high inflation in wages and services. Yael Selfin, chief UK economist at KPMG, made the following comment on the situation:
“While we are seeing some tentative signs of cooling in the labor market, service sector inflation remains persistently high and it is likely the MPC would want to wait until the next set of forecasts and a few more data points before it embarks on its first rate cut.”
Overall, UK inflation is expected to remain slightly above the BoE’s target of 2.0% in every quarter until at least the end of 2025, according to the poll. Median forecasts indicated that inflation would average 2.5% this year and 2.2% next year.
After reaching new highs in 2024, the FTSE 100 may attract more investors, particularly those focused on income accumulation. The projected dividend yield of 3.8% for 2024 and 4.1% for 2025 is appealing, especially since these yields surpass the current inflation rate. Analysts predict that the ten largest dividend-paying companies in the UK will return £43.9 billion to shareholders, accounting for 55% of the total dividends from the FTSE 100. The top 20 companies are expected to contribute £57.4 billion, making up 72% of the total dividends.
In 2023, UK dividend growth of 5.4% aligned with the global average, according to a report by Janus Henderson. This increase was driven by substantial dividend increases from banks and oil producers, although it was tempered by lower payouts from mining companies. The report further mentioned that annual dividends in the UK grew to $86 billion in 2023 from over $63 billion in 2020.
While investors gravitate toward American dividend stocks, some of the best FTSE dividend stocks also offer similar investment opportunities.
Our Methodology:
For this article, we scanned through the list of FTSE stocks and picked dividend stocks from the list. From the resultant dataset, we picked the 10 best FTSE dividend stocks with the highest number of hedge fund investors tracked by Insider Monkey as of Q1 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
A doctor and a patient discussing a therapy plan that includes pharmaceutical products.
GSK plc (NYSE:GSK)
Number of Hedge Fund Holders: 41
GSK plc (NYSE:GSK) is a leading global healthcare company that operates across various therapeutic areas, including vaccines, respiratory, and oncology. The company currently offers a quarterly dividend of $0.376 per share for a dividend yield of 3.67%. This stock is up by nearly 10% year-to-date, although it experienced volatility in the first week of June when shares dropped by over 9%. This decline occurred after a Delaware judge permitted over 70,000 lawsuits claiming that its discontinued heartburn medication Zantac led to cancer, posing a setback for the British pharmaceutical company. This ongoing uncertainty adds to a challenging decade for GSK, as the company continues to struggle with the need to replenish its pharmaceutical pipeline. However, with nearly 90 products currently in its R&D pipeline, it appears that the company is making significant progress.
From a dividend perspective, GSK plc (NYSE:GSK) can be a solid investment. Though the company’s dividend has encountered some challenges in the past, its cash position indicates that the company has enough resources on its balance sheet to sustain its payouts. In Q1 2024, the company generated over £1 billion ($1.26 billion) in operating cash flow and its free cash flow came in at £300 million ($379.47 million). During the quarter, it returned £568 million ($718.46 million) to shareholders through dividends, which places it on our list of the best FTSE dividend stocks.
GSK plc (NYSE:GSK) has a forward P/E of 10.21, lower than AstraZeneca’s forward P/E ratio of 18.94. Considering analysts’ estimates of an 8% revenue growth this year, GSK seems to be trading at a good value for a high-quality company.
The number of hedge funds tracked by Insider Monkey owning stakes in GSK plc (NYSE:GSK) grew to 41 from 40 during the first three months of 2024. These funds held in aggregate $2 billion worth of GSK shares at the end of March.
Overall GSK ranks 3rd on our list of the best FTSE dividend stocks to buy. You can visit 10 Best FTSE Dividend Stocks To Buy Now to see the other FTSE dividend stocks that are on hedge funds’ radar. While we acknowledge the potential of GSK as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than GSK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: Michael Burry Is Selling These Stocks and Jim Cramer is Recommending These Stocks.
Disclosure: None. This article is originally published at Insider Monkey.